Casgevy Now FDA Approved for 2 Years and Older with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
RegulatoryapprovedCasgevyPositive
AI Analysis
Summary
Vertex Pharmaceuticals announced FDA approval for Casgevy for the treatment of patients ages 2 years and older with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia, expanding the drug's approved patient population.
Outcome Details
FDA approval for expanded use in patients ages 2 years and older with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Importance:8/10
Sentiment:
0.85
FDA approvallabel expansionpediatric indicationrare diseasegene therapy
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 5, 2026 11:07 PM